Literature DB >> 2112635

Arginine supplementation and its effect on established peritonitis in guinea pigs.

S J Gonce1, M D Peck, J W Alexander, P W Miskell.   

Abstract

To evaluate the efficacy of supplemental arginine with nutritional support in the presence of sepsis, eighty-eight gastrostomized female Hartley guinea pigs were implanted with osmotic pumps effusing an Eschericia coli/Staphylococcus aureus mixture. Animals were randomized and infused for two weeks with isocaloric and isovolumetric diets containing 0%, 2%, 4%, or 6% supplemental arginine as arginine hydrochloride. Survival was 12/22 (54%) in 0%, 9/22 (41%) in 2% and 4%, and 2/22 (9%) in 6%. Analysis by chi-square test of independence was significant (p = 0.0141) with 6% survival lower than the others. Median survival was 11 days in 0%, 8 days in 2% and 6%, and 9 days in 4%. Median survival was longer in 0% than in 2% or 6% (Kruskal-Wallis ANOVA: p = 0.02). Nitrogen balance was significantly lower in 6% compared to 0% on days 2 through 10, and lower than 2% and 4% on days 6 and 9. Nitrogen balance was higher in 0% than in 2% on days 4, 6, 10, and 13. Serum albumin and C3 were lower in all experimental groups than normal controls (ANOVA: p = 0.01). Comparison of liver, spleen, adrenals, gastrocnemius, and carcass weights, cell-mediated immunity as determined by contact sensitivity to DNFB, and transferrin showed no significant differences. There was a positive dose-response effect seen amongst the experimental groups for the amino acids arginine, ornithine, and citrulline in relation to the amount of supplemental arginine. This study suggests that dietary arginine supplementation does not enhance survival in a guinea pig model of established peritonitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112635     DOI: 10.1177/0148607190014003237

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  9 in total

1.  Does pharmacological dose of parenteral arginine have beneficial effect in rats with sub-acute peritonitis?

Authors:  Hui-Chen Lo; Shih-Chi Wu; Yao-Horng Wang; Chien-Hsing Lee
Journal:  Pediatr Surg Int       Date:  2010-02-24       Impact factor: 1.827

Review 2.  Role of Arginine and Omega-3 Fatty Acids in Wound Healing and Infection.

Authors:  J Wesley Alexander; Dorothy M Supp
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-11-01       Impact factor: 4.730

Review 3.  The L-arginine/nitric oxide pathway--biological properties and therapeutic applications.

Authors:  P J Neilly; S J Kirk; K R Gardiner; B J Rowlands
Journal:  Ulster Med J       Date:  1994-10

Review 4.  Nutritional support in critically ill patients.

Authors:  J P Grant
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

Review 5.  Can arginine and ornithine support gut functions?

Authors:  L Cynober
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance. The role of nitric oxide.

Authors:  L Gianotti; J W Alexander; T Pyles; R Fukushima
Journal:  Ann Surg       Date:  1993-06       Impact factor: 12.969

Review 7.  Arginine depletion increases susceptibility to serious infections in preterm newborns.

Authors:  Shiraz Badurdeen; Musa Mulongo; James A Berkley
Journal:  Pediatr Res       Date:  2014-10-31       Impact factor: 3.756

Review 8.  Metabolic Regulation of Immune Responses to Mycobacterium tuberculosis: A Spotlight on L-Arginine and L-Tryptophan Metabolism.

Authors:  Rebecca R Crowther; Joseph E Qualls
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

9.  Use of sildenafil and L-arginine in an experimental rat model for the prevention of neonatal necrotizing enterocolitis.

Authors:  Gabriela Araujo Moreira; André Ivan Bradley Dos Santos Dias; Silvia Maria Suter Correia Cadena; Marília Locatelli Corrêa-Ferreira; Sergio Ossamu Ioshii; Camila Girardi Fachin
Journal:  Sci Rep       Date:  2022-04-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.